Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Kolumbiens nächster Kupferriese? Warum Investoren dieses 14.000-Meter-Bohrprogramm beobachten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
489 Leser
Artikel bewerten:
(2)

ASHTEAD GROUP PLC - Result of AGM

Finanznachrichten News

ASHTEAD GROUP PLC - Result of AGM

PR Newswire

Ashtead Group PLC
AGM Statement
6thSeptember 2022

ASHTEAD GROUP PLC
(the "Company")

AGM Statement & Results

AGM Statement & Results

At the Annual General Meeting of the Company "Ashtead Group plc" held on 6 September 2022 at 11:30am, all resolutions put to shareholders were duly passed on a poll with the required majorities. The full text of each resolution is contained in the Notice of Annual General Meeting. Resolutions 1 to 15 were passed as ordinary resolutions. Resolutions 16 - 19 were passed as special resolutions.

Issued Share Capital: 440,638,537

ORDINARY RESOLUTIONSVotes for (including discretionary votes)% Votes for *Votes against% Votes againstTotal no. of votes validly cast% of Issued Share Capital votedVotes
withheld**
1.That the accounts for the year ended 30 April 2022, the directors' report and the auditors' report be adopted.331,493,59299.481,745,6700.52333,239,26275.63%201,600
2.That the directors' remuneration report for the year ended 30 April 2022 be approved.224,285,28067.27109,133,31732.73333,418,59775.67%22,265
3.That the final dividend recommended by the directors of 67.5 cents
per ordinary share for the year ended 30 April 2022 be declared payable on 9 September 2022 to holders of ordinary shares registered at the close of business on 12 August 2022.
333,413,40299.9925,4690.01333,438,87175.67%1,991
4.That Paul Walker be re-elected as a director.320,433,21796.1013,001,1013.90333,434,31875.67%6,543
5.That Brendan Horgan be re-elected as a director.328,168,26498.425,266,8071.58333,435,07175.67%5,350
6.That Michael Pratt be re-elected as a director.332,134,42299.611,299,8970.39333,434,31975.67%6,543
7.That Angus Cockburn be re-elected as a director.323,842,82397.129,591,4962.88333,434,31975.67%6,543
8.That Lucinda Riches be re-elected as a director.249,645,77374.8783,788,54525.13333,434,31875.67%6,543
9.That Tanya Fratto be re-elected as a director.325,929,20197.757,505,1182.25333,434,31975.67%6,543
10.That Lindsley Ruth be re-elected as a director.325,891,06297.747,543,2572.26333,434,31975.67%6,543
11.That Jill Easterbrook re-elected as a director.325,869,66897.737,564,6512.27333,434,31975.67%6,543
12.That Renata Ribeiro be elected as a director.333,298,13799.96135,7410.04333,433,87875.67%6,543
13.That Deloitte LLP be re-appointed as auditor of the Company.323,117,69397.338,872,4372.67331,990,13075.34%1,450,732
14.That the directors be authorised to fix the remuneration of the
auditor of the Company.
327,861,23498.754,137,2891.25331,998,52375.34%1,442,339
15.That the directors are authorised to allot the shares under section 551 (1) (a) and (b) of the Companies Act 2006.320,765,75496.2012,668,0323.80333,433,78675.67%7,074

SPECIAL RESOLUTIONS
Votes for (including discretionary votes)% Votes for *Votes against% Votes againstTotal no. of votes validly cast% of Issued Share Capital votedVotes
withheld**
16.That the directors be empowered to disapply the provisions of section 561 (1) to (6) of the Companies Act 2006.331,424,43499.531,572,2570.47332,996,69175.57%444,171
17.That the directors be empowered to issue shares on a non
pre-emptive basis.
326,941,63998.186,055,3011.82332,996,94075.57%443,921
18.That the directors be authorised to make market purchases of the Company's shares under section 701 of the Companies Act.324,087,52097.249,207,6072.76333,295,12775.64%145,734
19.That a general meeting other than an annual general meeting may be called on not less than 14 clear days' notice.319,113,30895.7014,322,3554.30333,435,66375.67%5,198

* Includes discretionary votes

** A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "for" and "against" a resolution.

The Ashtead Board is pleased to note that all resolutions were passed with the requisite majority of votes and welcomes the overwhelming support of the Company's shareholders for the majority of the resolutions proposed.

The Company notes the disappointing level of shareholder support for resolution 2 (Approval of the Directors Remuneration Report) and resolution 8 (the re-election of the Remuneration Chair). Prior to last year's AGM , the Remuneration Committee undertook an extensive consultation with its largest shareholders on the proposed Directors' Remuneration Policy (the "Policy") and its implementation.

The Committee received indications of broad support during this process, but also took into account the full range of feedback received. As described in both the 2021 and 2022 Annual Reports, the Committee was very mindful of the need to balance sometimes divergent shareholder views with the particular context and circumstances for Ashtead, to ensure that remuneration policy continues to incentivise growth and long-term shareholder value creation. A number of changes were made to the performance targets of the Strategic Plan Award as a direct result of shareholder feedback at the time. However, the Committee also concluded that the other aspects of the proposals remained appropriately aligned to the Company's stated principles of providing remuneration that is: market competitive; enables the Company to motivate and retain its talented leadership team; and rewards fairly its colleagues' contribution to Ashtead's future success. The Policy and 2021 Directors' Remuneration Report were each approved by shareholders at the 2021 AGM.

Following the 2021 AGM, the Company responded to the level of support for the remuneration resolutions being below 80% by conducting another thorough engagement process involving approximately 50% of the shareholder register. Based on the further supportive responses received from those shareholders who accepted the invitation to meet as part of the process, the Remuneration Committee concluded that no further action or additional modifications to the Policy or the performance targets, or our approach to its implementation, was required. The outcome of this engagement was detailed in an RNS dated 11 March 2022 and in the Company's 2022 Annual Report.

The Company will continue to seek to engage with its shareholders in respect of the implementation of the Policy. In accordance with the UK Corporate Governance Code the Company will publish an update on this further engagement within six months of the 2022 AGM.

In accordance with Listing Rule 9.6.2, a copy of the special resolutions have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Contact:

Will Shaw - Investment Manager, 020 7726 9700

Maitland

James McFarlane - 0207 379 5151

© 2022 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.